Background: The prophylactic benefit of statins in reducing the incidence of contrast-induced acute kidney injury (CI-AKI) has been investigated in several studies with conflicting results. We sought to investigate whether statin pretreatment prevents CI-AKI in coronary artery disease (CAD) patients undergoing percutaneous coronary intervention (PCI).
Preventive Effect of Statin Pretreatment on

Introduction
Contrast-induced acute kidney injury (CI-AKI), an important complication that can occur after percutaneous coronary intervention (PCI) [1] [2] [3] , has been associated with both short-and long-term adverse outcomes, including the need for renal replacement therapy, major cardiac adverse events, and mortality [4] . Previous reports showed that approximately 10% of patients develop CI-AKI following PCI [4] . Several prophylactic strategies, including periprocedural hydration with normal saline, limiting the amount of contrast medium, and using iso-or low-osmolar contrast are well established measures for the prevention of CI-AKI [2, 3, [5] [6] [7] .
Statins are a class of drug that improves the lipid profile of patients and has been reported to have pleiotropic effects in the vasculature. A few studies focusing on statin treatment as a specific prophylactic agent against CI-AKI have been published with conflicting results [8] [9] [10] [11] [12] . Moreover, the supposed pleiotropic effects of preventing post-procedural AKI represent a wide-spread range of effects that they have been reported in aortic valve surgery as well, not only in coronary artery disease (CAD) patients [13] . The aim of this study was to investigate whether statin pretreatment prevents CI-AKI in CAD patients undergoing PCI. To address this issue, we analyzed consecutive CAD patients undergoing PCI who were enrolled in the Ibaraki Cardiovascular Assessment Study (ICAS) registry.
Methods
Study Design
The ICAS registry was designed as a retrospective multicenter observational study of CAD in Ibaraki prefecture in Japan. All consecutive CAD patients who underwent PCI at 12 cooperating centers were enrolled in this registry. Study subjects are summarized in Figure 1 . A total of 2657 patients were enrolled from April 2007 to April 2010. We excluded the patients on dialysis (n=83) and those who died within 7-days of PCI (n=56). Patients with no information regarding serial measurements of serum creatinine were also excluded (n=320). The study population thus comprised 2198 patients who were divided into 2 groups according to statin pretreatment: statin pretreatment group (n=839) and non-pretreatment group (n=1359). This study was approved by the institutional review boards or ethics committees of all participating institutions.
Clinical Data Collection
Patient demographic information, cardiovascular risk factors, laboratory findings, angiographic findings, and percutaneous procedural characteristics were recorded according to information on medical charts at initial enrollment in the registry. Oral medications prescribed before the PCI procedure were also assessed. Statin pretreatment was defined as taking a statin prior to contrast exposure. The serum concentration of creatinine was measured serially, before contrast exposure and at 24-, 48-, and 72-hour after PCI. When it was not available at 48-or 72-hour post PCI, we used data obtained within 1 week after contrast exposure. Estimated glomerular filtration rate (GFR) was calculated with the Modification of Diet in Renal Disease study equation modified for the Japanese population [14] and estimated GFR of <60ml/min/1.73m 2 was defined as chronic kidney disease. Contrast volume (CV) used during each PCI was collected, and the CV/GFR ratio was calculated by dividing CV by the baseline estimated GFR. The
Mehran risk score was calculated on the basis of information collected before the procedure. Briefly, this is a scoring system based on comorbidities and procedural risk factors, including hypotension, intra-aortic balloon pump use, heart failure, age >75 years, anemia, diabetes mellitus, volume of contrast, and renal function. Predicted incidences of CI-AKI are reported to be 7.5%, 14%, 26.1%, and 57.3% for scores of ≤5
(low risk), 6-10 (moderate risk), 11-15 (high risk), and ≥16 (very high risk), respectively [15] . Based on the baseline diagnostic angiogram, SYNTAX score was calculated using the algorithm which is available on the SYNTAX website [16] .
Follow-up Survey and Study Endpoint
All follow-up data and clinical events were surveyed once a year during the study period. Data for patients who were lost to follow-up were censored at the time of the last contact. The primary endpoint for the present analysis was the development of CI-AKI defined as an increase in serum creatinine of ≥25% or 0.5 mg/dl from the baseline within 1 week after contrast exposure [6] . The serum creatinine concentration
was not available at 48-or 72-hour in 25% of the patients; therefore, we used the data obtained within 1 week after contrast exposure. Secondary endpoints assessed included the composite and individual endpoint of requiring dialysis and/or all-cause death within 30, 180, and 360 days. All deaths were confirmed by medical charts or by contacting the referring physician and/or patient's family, and all events were registered by the attending physicians.
Statistical Analysis
Continuous variables are reported as mean ± SD or median and interquartile ranges, Goodness of fit of the propensity score was evaluated by the Hosmer-Lemeshow test and the c statistic. The propensity score was used in the following two ways. First, the derived propensity scores were used to match 565 statin pretreatment patients with non-pretreatment patients at a 1:1 ratio (Figure 1 ). The maximum difference in the propensity score allowed for a match was 0.015 [17] . Second, propensity scores were used for adjustment for multivariate analysis [17] . Multivariate logistic analysis was performed to determine the independent effect of statin pretreatment for the primary endpoint with stepwise backward elimination method according to a selection-stay criterion of P <0.05. Covariates included age, male sex, statin pretreatment, acute coronary syndrome, ejection fraction ≤45%, multivessel disease, and Mehran risk score.
When all subjects were analyzed, propensity scores were also incorporated into a subsequent multivariate model [17] . A two-sided P value of <0.05 was considered to be statistically significant throughout the analysis. Data were analyzed with IBM SPSS Statistics 18.0 for Windows (SPSS Inc., Chicago, IL).
Results
Baseline Patient Characteristics and Statin Use
We analyzed a total of 2198 consecutive CAD patients who underwent PCI in this study. Mean age was 69.5±10.7 years and 77% of patients were men. Before undergoing PCI, the prescription rate of statin was 38% among all patients. Of these, 82% of patients had been taking a statin ≥4 weeks before contrast exposure. The statins used were included; rosuvastatin 329, atorvastatin 172, pitavastatin 97, pravastatin 79, Table 1 . After propensity score matching, well-balanced distribution of the covariates was confirmed between with and without statin pretreatment groups.
Laboratory Data, Contrast Medium, and Mehran Risk Score
Laboratory data, contrast volume, and Mehran risk score are shown in Table 2 . The concentrations of total cholesterol and LDL cholesterol remained significantly different between the 2 groups even after propensity score matching. There were no significant differences in the CV/GFR ratio between the 2 groups. All procedures were performed with use of low-osmolar contrast medium. There was a significant difference in Mehran risk score between the 2 groups; however, this difference disappeared after propensity score matching.
Primary and Secondary Endpoints
Of the 2198 patients, 192 (8.7%) patients developed CI-AKI following PCI. In all patients, the incidence of CI-AKI was observed less frequently in those with statin pretreatment than in those without statin pretreatment (3.9% vs. versus without statin pretreatment, respectively), which was mainly attributed to the difference of mortality (Table 3) . After propensity score matching, however, there were no significant differences in secondary endpoint between the 2 groups (Table 3) .
Because receiver-operating characteristics analysis derived the cut-off value of Mehran risk score was 7, with a sensitivity of 74% and a specificity of 62% for predicting composite secondary endpoint, the subjects were recategorized according to the cut-off value of Mehran risk score (≤7 or >7) and statin pretreatment. Kaplan-Meier curves
showed that the patients with Mehran risk score of >7 and who did not receive statin pretreatment had worst clinical prognosis among all subjects ( Figure 3A ) and propensity score-matched subjects ( Figure 3B ).
Discussion
In the present study, we evaluated the role of statin pretreatment for prevention of CI-AKI among consecutive patients undergoing PCI. The present study comprised an observational cohort of consecutive CAD patients who were treated with PCI, and the major findings of the study are as follows. First, the incidence of CI-AKI was 8.7%
overall in consecutive and unselective patients who underwent PCI. The significant decrease in CI-AKI development following PCI was shown in patients with statin pretreatment after propensity score matching (OR: 0.31, 95% CI: 0.18-0.52, P<0.001).
The patients with Mehran risk score of ≤15 had substantial benefit for preventing CI-AKI, and statin pretreatment was a negative independent predictor for CI-AKI after adjusting for propensity score. Second, clinical outcomes including death and requiring dialysis within 30, 180, and 360 days following PCI were not significantly different between patients with and without statin pretreatment among propensity score-matched subjects.
The incidence of CI-AKI has been an important potential concern because of its effect on morbidity and mortality [4] . Although the pathogenesis of CI-AKI is not well known, it has been hypothesized to be due to oxidative stress, reduction in renal blood flow, tubular obstruction, and direct toxicity to tubular epithelium [1, 4, 18] . Statins are mainly used as lipid-lowering agents and are also known to have pleiotropic effects, including increased nitric oxide production, antioxidant effects, and anti-inflammatory properties [19, 20] . The rational for the use of statins for the prevention of CI-AKI relates to its pleiotropic effects, leading to reduction of renal oxidative stress and enhancement of renal nitric oxide. Recently, Quintavalle et al. showed that pretreatment with atrovastatin prevents contrast-induced renal cell apoptosis by reducing reactive oxygen species production in vitro model [21] .
There is general agreement that chronic kidney disease is the most crucial risk factor for CI-AKI, and CV is also a main procedure-related risk factor for CI-AKI [2, 4, 22] . The CV/GFR ratio has recently been reported to be a useful tool for predicting the development of CI-AKI, as well as the need for renal replacement therapy [6, 23] . The other important risk factors for CI-AKI include age over 70 years, diabetes, congestive heart failure, dehydration, and concurrent administration of nephrotoxic agents, i.e., non-steroid anti-inflammatory drugs [2, 4, 22, 24] . The mechanism and risk of CI-AKI are multifactorial, and therefore, identification of patients at high risk for the development of CI-AKI is of major importance. The Mehran risk score, based on comorbidities and procedural risk factors, is a scoring system that is useful for predicting the development of CI-AKI in patients undergoing non-emergent and emergent PCI [15, 25] . In this study, we opted to perform risk stratification by using the Mehran risk score, which makes our study relevant and unique. Although the patients with a Mehran risk score of ≥16 had a very high incidence of CI-AKI and showed no significant effects of statin pretreatment, statin pretreatment provided substantial benefit of CI-AKI prevention in the patients with Mehran risk score of ≤15 in our study. Multivariate logistic analysis showed that statin pretreatment was a negative independent predictor of CI-AKI development even after adjustment or matching for propensity score.
The prophylactic benefit of statin for reduction of CI-AKI incidence has been [12] .
The incidence of CI-AKI is associated with poor long-term clinical outcomes, but few studies of statin pretreatment have addressed long-term prognosis, such as requiring dialysis, morbidity, and mortality [18] . In our study, despite the significant decrease of CI-AKI with statin pretreatment, there were no significant differences in mortality and/or renal dysfunction requiring dialysis within 30, 180, and 360 days after propensity score matching. The considerable reason might be due to the current widespread use of statins for CAD patients after PCI. The effects of improving long-term clinical outcomes, such as mortality, as well as preventing CI-AKI, should be confirmed by well-designed, randomized controlled trial.
Study Limitations
Several limitations in the design of the ICAS registry should be mentioned. First, this study was based on a non-randomized observational retrospective design. The choice of statin was not allocated randomly but was decided by direction of the individual physician. Therefore, this might have introduced potential biases related to unmeasured or hidden covariates in selection of prescribed medications and leading to potential incomplete and/or inexact matching, even though multiple variables were adjusted by propensity score-matched and -adjusted analysis. Our study thus is inferior in comparative validity compared with a randomized, controlled trial. Moreover, because this study was an observational design, there were differences in the study subjects between with and without statin pretreatment on many of the measured covariates. We controlled for these between-group differences using propensity score-matching in order to attenuate the impact of treatment selection bias when estimating causal treatment effects. Propensity score-matching commonly entails creating pairs of treated and untreated subjects who have similar values of propensity score. However, a limitation to matching is the reduction in sample size that arises from regarding unmatched subjects.
In our study, an appropriate match could not be identified for 32 % of patients with statin treatment after propensity score-matching. Despite this reduction in sample size, the significance of statin pretreatment for preventing CI-AKI was consistent in this analysis. Second, the collection of creatinine following PCI was constituted retrospectively, and it was difficult to obtain 48-or 72-hour measurement of serum creatinine for all patients, thereby leading to the use of an alternative solution by 1-week measurement in 25% of the whole patients. However, we observed a similar relation in patients who had both 48-or72 -hour and 1-week measurement of serum creatinine, and thus our overall findings are likely extant. Third, there was a lack of precise information on statin dosing and noncompliance, and safety data was insufficient during the follow-up period. Forth, serum level of creatinine, especially in the elderly and female populations, who have low muscle mass, is an inexact measure of renal function.
Fifth, the prevalence of CAD and the cholesterol level of the Japanese population are different from that of Western populations [26] . Japanese patients are more susceptible to statin treatment than are Westerners [27] . Other limitations included the lack of data regarding potential other nephrotoxic agents, such as non-steroidal anti-inflammatory drugs, in the present study. Despite these study limitations, we found that statin pretreatment was associated with a significant decrease in CI-AKI development in CAD patients who underwent PCI.
Conclusions
Our observational cohort analysis showed that statin pretreatment was associated with a significant decrease in the incidence of CI-AKI in CAD patients undergoing PCI.
These results could not be incorporated to the subgroup of very high value of Mehran risk score, because of underpowered detecting significance of CI-AKI prevention. A large-scale, well-designed, multicenter randomized controlled trial would be necessary to address the effects of statin for preventing CI-AKI, as well as improving long-term clinical outcomes. Free from death or dialysis Values are mean ± SD, median [first and third quartiles] or n (%).
ACEI indicates angiotensin converting enzyme inhibitor; ARB = angiotensin II receptor blocker; CABG = coronary artery bypass grafting; CVD = cardiovascular disease; LAD = left anterior descending artery; PCI = percutaneous coronary intervention; and PS = propensity score. Values are mean ± SD or n (%).
CV/GFR indicates contrast volume/estimated glomerular filtration rate; GFR = glomerular filtration rate; HDL = high-density lipoprotein; LDL = low-density lipoprotein; and PS = propensity score. 
